Xenon Pharmaceuticals Inc. (XENE): Among the Best Mid-Cap Healthcare Stocks To Buy Now
RBC Capital Maintains Xenon Pharmaceuticals(XENE.US) With Buy Rating, Maintains Target Price $55
RBC Capital analyst Brian Abrahams maintains $Xenon Pharmaceuticals(XENE.US)$ with a buy rating, and maintains the target price at $55.According to TipRanks data, the analyst has a success rate of 49.
Insiders At Xenon Pharmaceuticals Sold US$1.6m In Stock, Alluding To Potential Weakness
Xenon Pharmaceuticals Appoints New COO
Press Release: Xenon Expands Leadership Team With Matthew D. Ronsheim, Ph.D. as Chief Operating Officer
Needham Maintains Buy on Xenon Pharmaceuticals, Lowers Price Target to $60